The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial

Endocrine ◽  
2017 ◽  
Vol 57 (1) ◽  
pp. 51-59 ◽  
Author(s):  
Shabnam Salekzamani ◽  
Abolhassan Shakeri Bavil ◽  
Hossein Mehralizadeh ◽  
Mohammad Asghari Jafarabadi ◽  
Aymaral Ghezel ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Vitamin D ◽  
Inflammatory Markers ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Vitamin D Supplementation ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Contributions of Vitamin D in the management of depressive symptoms and cardiovascular risk factors: study protocol for a randomized, double-blind, placebo-controlled clinical trial

2019 ◽  
Author(s):  
Catarina Magalhaes Porto ◽  
Tatiana de Paula Santana da Silva ◽  
Everton Botelho Sougey
Keyword(s):  
Risk Factors ◽  
Clinical Trial ◽  
Vitamin D ◽  
Depressive Symptoms ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Vitamin D Supplementation ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background Depression, the leading cause of chronic disability worldwide, comprises an important cardiovascular risk factor, increasing the relative risk of coronary artery disease and cardiovascular morbidity and mortality. Concomitant with the higher prevalence of depression, there is also a reduction in exposure to sunlight, with increased urbanization and industrialization and the use of sunscreens leading to a decrease in serum levels of 25-hydroxyvitamin D. In this sense, this essay intends to evaluate the action supplementation with vitamin D in the management of depressive symptoms and cardiovascular risk factors, increasing the limited evidence on the potential effects of supplementation in situations related to mood regulation. Methods This is a randomized, double-blind, placebo-controlled clinical trial, built in accordance with SPIRIT, involving 224 adults aged 18-59 years with depression on antidepressants, no history of vitamin D supplementation, psychiatric comorbidities, chronic kidney disease, hypercalcemia, and neoplasms, attended at the psychiatric outpatient clinics of two universities in northeastern Brazil. Consent and eligible participants will be randomly assigned to the intervention groups (n = 112) who will receive vitamin D supplementation, 50,000 IU weekly for six months, and control (n = 112) who will use weekly placebo for six months. Measurements for the monitoring of depressive symptoms, clinical trials, and laboratory tests to assess cardiovascular risk factors and serum vitamin D levels will be performed at the beginning, during and after the intervention period. Discussion This is the first trial to test the efficacy of vitamin D supplementation in reducing cardiovascular risk and as adjuvant to antidepressant therapy over a long period (six months). The obtained results will support the understanding of the therapeutic effects of vitamin D supplementation in the management of mood disorders, as well as corroborate in the direction of public policies aimed at vitamin supplementation to prevent cardiovascular risk.

Effects of magnesium supplementation on carotid intima–media thickness and metabolic profiles in diabetic haemodialysis patients: a randomised, double-blind, placebo-controlled trial

2019 ◽  
Vol 121 (7) ◽  
pp. 809-817 ◽  
Author(s):  
Hamid Reza Talari ◽  
Mehrafrouz Zakizade ◽  
Alireza Soleimani ◽  
Fereshteh Bahmani ◽  
Amir Ghaderi ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Insulin Metabolism ◽  
Double Blind Placebo ◽  
Media Thickness ◽  
Hs Crp

AbstractThis study evaluated the effects of Mg administration on carotid intima–media thickness (CIMT), glycaemic control and markers of cardio-metabolic risk in diabetic haemodialysis (HD) patients. This randomised, double-blind, placebo-controlled clinical trial was conducted in fifty-four diabetic HD patients. Participants were randomly divided into two groups to take either 250 mg/d Mg as magnesium oxide (n27) or placebo (n27) for 24 weeks. Mg supplementation resulted in a significant reduction in mean (P<0·001) and maximum levels of left CIMT (P=0·02) and mean levels of right CIMT (P=0·004) compared with the placebo. In addition, taking Mg supplements significantly reduced serum insulin levels (β=–9·42 pmol/l; 95% CI –14·94, –3·90;P=0·001), homoeostasis model of assessment-insulin resistance (β=–0·56; 95 % CI –0·89, –0·24;P=0·001) and HbA1c (β=–0·74 %; 95 % CI –1·10, –0·39;P<0·001) and significantly increased the quantitative insulin sensitivity check index (β=0·008; 95 % CI 0·002, 0·01;P=0·002) compared with the placebo. In addition, Mg administration led to a significant reduction in serum total cholesterol (β=–0·30 mmol/l; 95% CI –0·56, –0·04;P=0·02), LDL-cholesterol (β=–0·29 mmol/l; 95% CI –0·52, –0·05;P=0·01), high-sensitivity C-reactive protein (hs-CRP) (P<0·001) and plasma malondialdehyde (MDA) (P=0·04) and a significant rise in plasma total antioxidant capacity (TAC) levels (P<0·001) compared with the placebo. Overall, we found that taking Mg for 24 weeks by diabetic HD patients significantly improved mean and maximum levels of left and mean levels of right CIMT, insulin metabolism, HbA1c, total cholesterol and LDL-cholesterol, hs-CRP, TAC and MDA levels.

Sign in / Sign up

Export Citation Format

Share Document